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Background: Neurotropic arboviruses are increasingly 
recognised as causative agents of neurological dis-
ease in Europe but underdiagnosis is still suspected. 
Capability for accurate diagnosis is a prerequisite for 
adequate clinical and public health response. Aim: To 
improve diagnostic capability in EVD-LabNet labora-
tories, we organised an external quality assessment 
(EQA) focusing on molecular detection of Toscana 
(TOSV), Usutu (USUV), West Nile (WNV) and tick-borne 
encephalitis viruses (TBEV). Methods: Sixty-nine labo-
ratories were invited. The EQA panel included two WNV 
RNA-positive samples (lineages 1 and 2), two TOSV 
RNA-positive samples (lineages A and B), one TBEV 
RNA-positive sample (Western subtype), one USUV 
RNA-positive sample and four negative samples. The 
EQA focused on overall capability rather than sensi-
tivity of the used techniques. Only detection of one, 
clinically relevant, concentration per virus species and 
lineage was assessed. Results: The final EQA analy-
sis included 51 laboratories from 35 countries; 44 of 
these laboratories were from 28 of 31 countries in the 
European Union/European Economic Area (EU/EEA). 
USUV diagnostic capability was lowest (28 laboratories 
in 18 countries), WNV detection capacity was highest 
(48 laboratories in 32 countries). Twenty-five labora-
tories were able to test the whole EQA panel, of which 
only 11 provided completely correct results. The high-
est scores were observed for WNV and TOSV (92%), 
followed by TBEV (86%) and USUV (75%). Conclusion: 
We observed wide variety in extraction methods and 
RT-PCR tests, showing a profound absence of stand-
ardisation across European laboratories. Overall, the 
results were not satisfactory; capacity and capability 
need to be improved in 40 laboratories.
Background
The aetiology of neuro-invasive viral infections remains 
undetermined in more than 50% of cases [1]. Several 
viruses can cause infections of the central nervous 
system (CNS) while, regardless of the causative aeti-
ology, clinical manifestations are often similar, making 
a confirmed diagnosis dependant on laboratory test-
ing [2]. Neurotropic arboviruses are increasingly rec-
ognised as causative agents of neurological disease 
in Europe but underdiagnosis is still suspected [3]. 
Confirmed involvement of arboviruses is important for 
risk communication and risk management strategies, 
the latter including activities like local vector control, 
blood safety measures and vaccination campaigns. 
Four neurotropic arboviruses are emerging and have 
become endemic in large parts of Europe: Toscana virus 
(TOSV), Usutu virus (USUV), West Nile virus (WNV) and 
tick-borne encephalitis virus (TBEV).
The TOSV (genus Phlebovirus,  family Phenuiviridae) is 
transmitted by sandflies of the genus Phlebotomus and 
circulates in Mediterranean countries where it can 
cause febrile illness and neuroinvasive infections. At 
least 250 million people are exposed in Europe and 
neighbouring countries around the Mediterranean 
basin that are frequently visited by travellers for occu-
pational or leisure purposes [4–7]. In France, Spain and 
Italy, TOSV is among the three most common agents 
causing aseptic meningitis and encephalitis, together 
with enteroviruses and herpesviruses (herpes simplex 
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and varicella–zoster viruses) [8]. Viraemia is short-
lived (typically 5 days, range: 2–7) and diagnosis is 
done either by detecting viral RNA in cerebrospinal 
fluid (CSF) or serum at the acute stage of infection 
or by detecting IgM in an early serum sample [8]. The 
currently known circulation of three genetic lineages 
may be indicative of a wide genetic diversity of this 
viral species and thus molecular assays are needed to 
detect genetic variants [8].
WNV (genus  Flavivirus, family  Flaviviridae) is trans-
mitted by  Culex  spp. mosquitoes. WNV can cause 
febrile illness with or without neurological manifesta-
tions. During the last decade, WNV activity in Europe 
has shown a profile similar to that observed in North 
America, with substantial activity reported every year 
and with recurring major outbreaks [9,10]. Major recent 
activity in the eastern Mediterranean region is also a 
matter of concern for Europe [11].
Lineages 1 and 2 have been identified in human WNV 
cases in Europe [12]. Severe cases are more frequent in 
elderly and immunocompromised patients. In the acute 
stage of disease, WNV RNA can be detected in CSF. 
WNV viraemia is typically short-lived, but viral RNA 
can be detected for longer periods in some specimens 
such as urine and whole blood, and also in fatal cases 
or immunocompromised patients. The high degree of 
cross-reactivity with other flaviviruses in serology is 
problematic. Although a combination of serology and 
PCR is desirable, the detection of WNV RNA alone is an 
important means of undisputable confirmation of acute 
infection [13].
USUV (genus  Flavivirus, family  Flaviviridae) was first 
isolated in Africa in 1959 [13]. It is a Culex-transmitted 
flavivirus closely related to WNV [13]. The earliest 
human cases (presenting as neuro-invasive disease) 
were recorded in 2009 in Italy in two immunocompro-
mised patients having received blood products [13]. 
Since then evidence of zoonotic transmission accom-
panied by neurological disease of USUV is accumulat-
ing while population studies show the occurrence of 
asymptomatic infections [13]. Nothing is known about 
the length of USUV viraemia and the kinetics of anti-
body production in humans [13]. Based on its close 
relatedness to WNV, viraemia is expected to be short 
and low level [13]. At the acute stage of neuroinvasive 
infection the virus is expected to be detectable by 
RT-PCR in CSF. A high degree of cross-reactivity with 
other flaviviruses is seen in serology. For this reason, 
molecular detection is the preferred method for con-
firmatory laboratory diagnosis.
TBEV (genus  Flavivirus, family  Flaviviridae) is a tick-
borne flavivirus; the incidence of TBEV infection 
in humans and its geographical distribution have 
increased in Europe [14]. Three subtypes are recog-
nised, of which the Western subtype is endemic in 
northern, central and eastern Europe. The clinical 
spectrum of the disease ranges from mild meningi-
tis to severe meningoencephalitis. The course of TBE 
is often biphasic. The first acute phase typically has 
Table 1
Nucleic acid extraction methods used in the external quality assessment for molecular detection of emerging neurotropic 
viruses, Europe (n = 51 laboratories)
Extraction method Number of laboratories
QIAamp Viral RNA Mini Kit (Qiagen, Hilden) 21
NucliSENSE EasyMag (BioMérieux, Marcy-L’étoile) 4
EZ1 Virus Mini Kit (Qiagen, Hilden) 3
MagNA Pure 96 DNA and Viral NA kit (Roche, Meylan) 3
RNeasy Mini kit (Qiagen, Hilden) 2
QIAamp MinElute Virus Spin Kit (Qiagen, Hilden) 2
MagNa Pure LC total NA kit (Roche, Meylan) 2
MagNa Pure Compact NA isolation kit (Roche, Meylan) 2
iPrep PureLink Virus Kit (Thermo Fisher, Bourgoin-Jallieu) 2
QIAamp DSP Virus (Qiagen, Hilden) 1
Maxwell RSC Viral Total NA Purification Kit (Promega, Charbonnières-les-Bains) 1
QIAxtractor VX (Qiagen, Hilden) 1
QIAamp RNA Blood Mini Kit (Qiagen, Hilden) 1
MagCore Viral NA extraction kit (RBCBioscience, New Taipei City) 1
TriPure isolation reagent (Sigma-Aldrich, Saint-Louis) 1
High Pure Viral RNA kit (Roche, Meylan) 1
NucleoSpin RNA Virus (Macherey-Nagel, Düren) 1
MagDea NA extraction kit for magLead (PSS-Ltd, Tokyo) 1
RIBO-prep NA extraction kit (AmpliSense, Voisins-Le-Bretonneux) 1
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non-specific symptoms. It is followed by an asympto-
matic interval that precedes the second phase char-
acterised by neuroinvasive disease. Therefore, the 
window of molecular detection in serum and CSF is 
often missed as diagnostics are typically requested 
during the second phase of illness. Once neurological 
symptoms are manifest, TBEV RNA is rarely detected 
in blood and CSF. However, in endemic regions, unex-
plained febrile illness alone can justify molecular test-
ing. As TBEV cases often do not present with typical 
symptoms, diagnosis often relies on laboratory docu-
mentation. As for WNV, viraemia is typically short-lived 
and low while serology is hampered by extensive cross-
reactivity among flaviviruses [15].
To support molecular diagnostic capacity and capability 
building for these emerging neurotropic viruses in the 
European Union(EU)/ European Economic Area (EEA) 
and EU pre-accession countries, an external quality 
assessment (EQA) was organised for members of the 
expert laboratory network EVD-LabNet (https://www.
evd-labnet.eu/) funded by the European Centre for 
Disease Prevention and Control. Here, we present this 
assessment and the inventory of methods for RT-PCR 
detection of these viruses that are used in European 
and national reference laboratories.
Methods
EQA scheme organisation
All members of EVD-LabNet (69 laboratories at 1 
November 2017) were invited by email to participate 
through online registration. Fifty-four laboratories from 
35 countries registered online.
Panel composition
The EQA panel consisted of 10 samples with six 
samples positive for one of four different viral spe-
cies (plasma samples spiked with viruses), and four 
negative control samples. The panel included two 
Figure 1
Number of laboratories per country that provided results for Toscana virus, external quality assessment for molecular 
detection of emerging neurotropic viruses, Europe (n = 32 laboratories)
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WNV RNA-positive samples (WNV lineage 1, strain 
UVE/WNV/2001/FR/DON2001 (ref#001V-02215), 
7.2 × 104  RNA copies/0.4 mL [16] and WNV lineage 
2, strain B956 source BNI, Hamburg, 4.96 × 105  RNA 
copies/0.4 mL), two TOSV RNA-positive samples 
(TOSV lineage A, strain UVE/TOSV/2010/TN/ T152 
(ref#001V-02119), 1.57 × 105  RNA copies/0.4 mL [17] 
and TOSV lineage B, strain UVE/TOSV/2010/FR/4319 
(ref#001V-02442), 1.24 × 105  RNA copies/0.4 mL [18]), 
one TBEV RNA-positive sample (Western subtype, 
strain UVE/TBEV/1953/CZ/Hypr (ref#001V-EVA134), 
5.06 × 104  RNA copies/0.4mL [19]), one USUV RNA-
positive sample (USUV, strain  Turdus merula  NL2016 
(ref#011V-02153), 6.34 × 103  RNA copies/0.4 mL) [20] 
and four viral RNA-negative plasma samples. Strains 
referenced in the European Virus Archive (EVA) can be 
accessed at https://www.european-virus-archive.com.
Each sample of the panel was prepared from a batch 
that consisted of qualified non-therapeutic human 
plasma obtained from the French blood bank, spiked 
with virus culture supernatant and heat-inactivated at 
60 °C for 1 hour. A total of 70 0.4-mL aliquots were pre-
pared and freeze-dried into glass vials. Proper inactiva-
tion was confirmed by the absence of cytopathic effect 
in Vero cells and by undetectable increase of the viral 
RNA titre in the supernatant 5 days after inoculation. 
The viral loads per reconstituted sample were quanti-
fied with reference to in-house TOSV-, WNV-, TBEV- 
and USUV-specific synthetic RNA controls; a fragment 
(ca 500 bp) tagged at the 5’end with the T7 promoter 
sequence (5’TAATACGACT CACTATAGGG3’) and con-
taining the virus-specific TaqMan-targeted sequence 
was amplified by RT-PCR using the Access RT-PCR 
kit (Promega, Charbonnières-les-Bains). The result-
ing PCR products were purified and transcribed using 
the T7 Megashort script kit (Ambion, ThermoFisher 
Scientific, Bourgoin-Jallieu). The obtained RNA was 
purified with the MegaClear purification kit (Ambion, 
Bourgoin-Jallieu). RNA concentration was measured 
using a NanoDrop 1000 (Thermo Scientific, Bourgoin-
Jallieu) and translated into copy numbers. Real-time 
RT-PCR was performed using the Express One-Step 
Superscript qRT-PCR Kit, universal (Life technologies, 
Bourgoin-Jallieu) on a QuantStudio 12K Flex Real-Time 
PCR System. For each EQA sample, the number of cop-
ies contained in 0.4 mL of freeze-dried material in the 
glass vial was calculated by comparison with a dilution 
series of T7-generated RNA standard containing 102  to 
108 RNA copies.
Result submission, evaluation and EQA scoring
We provided the Laboratories with a link to an online 
form to submit their EQA results. Laboratories could 
indicate for which of the four target viruses they had 
tested the EQA panel and background information of 
the diagnostic tests that the laboratory assessed with 
the EQA. Data were collected and analysed in Microsoft 
Excel 2011. Fisher’s exact test (www.socscistatistics.
com/tests/fisher/Default2.aspx) was used to compare 
the rate of false-negative results obtained with virus-
specific real-time assays and with other assays for 
TOSV, USUV, TBEV and WNV. Fisher’s exact test was 
used because the significance of the deviation from a 
null hypothesis can be calculated exactly, rather than 
relying on an approximation that becomes exact in the 
Table 2
RT-PCR methods used for Toscana virus RNA detection, external quality assessment for molecular detection of emerging 
neurotropic viruses, Europe (n = 32 laboratories).
Target Method Number of laboratories False-negativea
Toscana virus-specific
TOSV N Perez-Ruiz et al., 2007 [29]b 13 1 (lineage B)
TOSV N Weidmann et al., 2008 [30]b 5 None
TOSV N Brisbarre et al., 2015 [31]b 2 None
TOSV L Sanchez-Seco et al., 2003 [43]c 1 1 (lineage B)
TOSV various Own designd 5 1 (lineage B)
TOSV N Progenie (commercial)b 1 None
Pan-phlebovirus
Pan-phlebo L/Ne Sanchez-Seco et al., 2003 [43] 7
1 (lineage A), 
 
2 (lineage B)
Pan-phlebo N Lambert and Lanciotti, 2009 [44] 1 1 (lineage B)
Pan-phlebo unknown Own designd 1 None
TOSV: Toscana virus.
a The missed TOSV lineage is indicated between brackets.
b Included in statistical analysis as classified as virus-specific real-time RT-PCR.
C Included in statistical analysis as classified as conventional RT-PCR.
d Excluded from statistical analysis as no distinction could be made whether it is real-time RT-PCR or conventional RT-PCR.
e Not all participants indicated which of two pan-Phlebo RT-PCRs in the reference was used.
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limit as the sample size grows to infinity, as with the 
chi-squared test.
Results
EQA participation
The final EQA analysis included 51 laboratories form 35 
countries: 44 laboratories from 28 EU/EEA countries, 
four laboratories from four EU pre-accession coun-
tries (Albania, North Macedonia, Serbia and Turkey) 
and three laboratories from three non-EU/EEA coun-
tries (Israel, Russia and Switzerland). From the EU/
EEA, there was no participation from laboratories in 
Iceland and France besides the reference laboratory in 
Marseille that produced the panel. Liechtenstein does 
not have a reference laboratory participating in EVD-
LabNet. From EU pre-accession countries, there was no 
participation by Bosnia and Herzegovina, Montenegro 
and Kosovo*, the two latter being not members of EVD-
LabNet at the time.
Nucleic acid extraction methodology
The different techniques used for extraction of nucleic 
acids are presented in the Table 1. Various Qiagen kits 
were used by 31 laboratories: 21 used the QIAamp Viral 
RNA Mini Kit (Qiagen, Hilden) and the remaining 10 
laboratories used six different Qiagen kits. The extrac-
tion kits from Roche (Meylan) were the second most 
frequently used brand, with eight laboratories using 
four different types of Roche kits. Because of the high 
diversity, it was impossible to include the type of RNA 
purification in the analysis.
Toscana virus
Of the 51 laboratories, 32 laboratories in 19 countries 
(17 EU/EEA, one EU candidate, one other) tested the 
panel for the presence of TOSV RNA (Figure 1). Nineteen 
laboratories in 19 countries had no TOSV test availa-
ble. Seven laboratories used a pan-phlebovirus RT-PCR 
only, 23 laboratories a TOSV-specific RT-PCR only and 
two laboratories used both type of tests in combina-
tion. Some laboratories used more than one TOSV-
specific or pan-phlebovirus test (Table 2).
Excluding TOSV-specific assays for which no informa-
tion was available (n = 10), TOSV-specific real-time 
tests (n = 42) provided false-negative results signifi-
cantly less frequently than all other tests together (pan-
phlebo, classic and nested RT-PCR; n = 20; p = 0.011). 
Thirty-one of the 32 laboratories detected TOSV RNA 
correctly in sample #1 (lineage A) and 28 laboratories 
detected TOSV RNA correctly in sample #2 (lineage B). 
The RT-PCR tests used by laboratories that missed the 
presence of TOSV in sample #1 (n = 1) or in sample #2 
(n = 6) are presented in Table 2. One laboratory falsely 
detected TBEV RNA besides TOSV RNA in sample #1 
(Table 3).
West Nile virus
Forty-eight laboratories in 32 countries (26 EU/EEA, 
four EU candidates and two other) tested the panel for 
WNV RNA (Figure 2). One laboratory used a pan-flavi 
RT-PCR test while 28 laboratories used a WNV-specific 
RT-PCR. Eighteen laboratories used both a pan-flavi 
and WNV-specific RT-PCR, but the questionnaire did 
not allow linking the result with either assay. One 
laboratory did not report what type of test was used. 
Some laboratories used more than one RT-PCR test 
(Table 4). The diversity of WNV-specific tests used was 
high with a total of 25 different tests. Excluding WNV-
specific assays for which no information was available 
(n = 4), there was no statistically significant difference 
Table 3
Summary of results of laboratories in the external quality assesment on molecular diagnostics of emerging neurotropic 
viruses, Europe (n = 51)
Sample ID 1a 2 3 4 5 6 7 8 9 10
Virus
TOSV 
(lineage 
A)
TOSV 
(lineage 
B)
USUV
WNV 
(lineage 
1)
WNV 
(lineage 
2)
TBEV Negative Negative Negative Negative
Concentration
1.57 x 
105 RNA 
cp/0.4mL
1.24 x 
105 RNA 
cp/0.4mL
6.34 x 
103 RNA 
cp/0.4mL
7.2 x 
104 RNA 
cp/0.4mL
4.96 x 
105 RNA 
cp/0.4mL
5.06 x 
104 RNA 
cp/0.4mL
n/a n/a n/a n/a
Total correct positive when 
tested for the specific virus 31/51 28/51 23/51 42/51 46/51 37/51 n/a n/a n/a n/a
Total correct positive when 
not tested for the specific 
virus
17/51 18/51 19/51 2/51 2/51 8/51 n/a n/a n/a n/a
Total correct 48/51 46/51 42/51 44/51 48/51 45/51 47/51 48/51 49/51 48/51
Total partially correct: 
identification at the genus 
level
0/51 0/51 1/51 2/51 1/51 2/51 n/a n/a n/a n/a
False 4/51 5/51 5/51 5/51 2/51 4/51 3/51 3/51 1/51 3/51
Total sentivity 31/32 28/32 21/28 42/48 46/48 36/42 n/a n/a n/a n/a
n/a: not applicable; TBEV: tick-borne encephalitis virus; TOSV: Toscana virus; USUV: Usutu virus; WNV: West Nile virus.
a Number > 100% as one laboratory submitted both a correct result (positive for TOSV) and one false result (positive for TBEV) for this sample.
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between results provided by WNV-specific real-time 
tests (n = 29) and all other tests together (real-time 
pan-flavi, classic and nested RT-PCR; n = 22; p = 0.38).
Forty-two of 48 laboratories that tested the panel for 
the presence of WNV RNA detected WNV RNA correctly 
in sample #4 (lineage 1), while one laboratory indicated 
to have detected flavivirus RNA. Five laboratories 
falsely scored sample #4 as negative. WNV RNA was 
correctly identified in sample #5 (lineage 2) by 46 of 48 
laboratories. Of the two laboratories providing a false-
negative result for sample #5, one laboratory reported 
the presence of TBEV RNA in sample #5; the other 
reported the presence of flavivirus RNA, although it did 
not claim to test for WNV (Table 3).
Usutu virus
Twenty-eight laboratories in 18 countries (16 EU/EEA, 
two other) tested the panel for USUV (Figure 3). Six 
laboratories used a pan-flavivirus RT-PCR test only, 
15 used an USUV-specific RT-PCR only and seven used 
both a pan-flavivirus and USUV-specific RT-PCR, but it 
was impossible to trace which one was used to provide 
the submitted results. Some laboratories used more 
than one USUV-specific or pan-flavivirus RT-PCR test. 
There was a lot of variation in USUV-specific RT-PCRs 
used, with 17 different test systems (Tables 3 and 5).
Excluding USUV-specific assays for which no informa-
tion was available (n = 4), USUV-specific real-time tests 
(n = 20) provided false negative results significantly 
less frequently than all other tests together (real-time 
pan-flavi, classic and nested RT-PCR; n = 15; p = 0019). 
Seven of the 28 laboratories that tested the panel for 
USUV missed the positive sample #6. The RT-PCR tests 
used by these laboratories are indicated in Table 5.
Tick-borne encephalitis virus
Forty-two laboratories in 28 countries (25 EU/EEA, 
three other) tested the panel for TBEV RNA (Figure 4): 
seven used a pan-flavi RT-PCR test only, 24 used a 
TBEV-specific RT-PCR only and 11 used both a pan-flavi 
and TBEV-specific RT-PCR, however, the questionnaire 
Figure 2
Number of laboratories per country that provided results for West Nile virus, external quality assessment for molecular 
detection of emerging neurotropic viruses, Europe (n = 48 laboratories)
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did not permit to trace submitted results to one or the 
other assay. Moreover, some laboratories used more 
than one pan-flavivirus test. Table 6 gives an overview 
of the different RT-PCRs tests that were used on the 
EQA panel to detect TBEV RNA.
Excluding TBEV-specific assays for which no infor-
mation was available (n = 4), there was no statisti-
cally significant difference between results provided 
by TBEV-specific real-time tests (n = 29) and all other 
tests together (real-time pan-flavi, classic and nested 
RT-PCR n = 25; p = 1).
Thirty-six of 42 laboratories that tested the panel for 
the presence of TBEV RNA detected TBEV RNA correctly 
in sample #3. Four laboratories falsely scored sample 
#3 as negative including those using two commercial 
tests. One laboratory falsely indicated the presence of 
WNV RNA. One laboratory scored sample #3 as pan-
flavi-positive only (Table 3).
Contamination
Contamination issues were noticed in six of the 51 par-
ticipating laboratories. Contamination issues involved 
detection of flavivirus, Zika virus, WNV or TBEV RNA in 
the negative control samples or in samples containing 
other specific viruses.
Discussion
Fifty-one laboratories from 35 countries (28 EU/EEA, 
four EU pre-accession, three non-EU/EEA) participated 
in this EQA on molecular detection of emerging neu-
rotropic viruses. Twenty-five laboratories in 16 coun-
tries (15 EU/EEA, one non-EU/EEA) reported capacity 
for testing of all four EQA target viruses. However, only 
11 of the 25 scored the panel 100% correct. These 11 
laboratories represented 10 EU/EEA countries and 
one non-EU/EEA country. Overall, the results of the 
EQA are not satisfactory. The capacity and capability 
for molecular detection needs to be improved in the 
vast majority of the participating laboratories because 
these four viruses demonstrate a growing burden on 
Table 4
RT-PCR methods used for West Nile virus RNA detection, external quality assessment for molecular detection of emerging 
neurotropic viruses, Europe (n = 48 laboratories)
Target Method Number of laboratories False-negativea
West Nile virus-specific
WNV 5‘-UTR/C Linke et al., 2007 [45]b 11 1 (lineage 2)
WNV NS2A Eiden et al., 2010 [46]b 2 None
WNV 3‘-UTR Tang et al., 2006 [47]b 1 None
WNV 3’UTR Lanciotti et al., 2000 [48]b 1 None
WNV E/NS1 Shi et al., 2001 [49]b 1 None
WNV NS3 Chaskopoulou et al., 2011 [50] 1 None
WNV various Own design 3 1 (lineage 1)
WNV unknown Altona RealStar (commercial)b 5 1 (lineage 2)
WNV unknown Qiagen Artus (commercial)b 3 1 (lineage 1)
WNV unknown Fast Track Tropical fever Core (commercial)b 3 1 (lineage 1)
WNV unknown Sacace (commercial)b 1 None
WNV unknown Amplisense (commercial)b 1 None
Pan-flavivirus
Pan-flavi NS5 Scaramozzino et al., 2001 [51] 7 None
Pan-flavi NS5 Sanchez-Seco et al., 2005 [52] 3 None
Pan-flavi NS5 Moureau et al., 2007 [53] 2 1 (lineage 1)
Pan-flavi NS5 Patel et al., 2013 [54] 2 None
Pan-flavi NS5 Briese et al., 1999 [55] 1 None
Pan-flavi NS5 Vina-Rodriguez et al., 2017 [56] 1 None
Pan-flavi NS5 Vazques et al., 2012 [57] 1 None
Pan-flavi unknown Own design 2 None
Pan-flavi unknown Genekam (commercial) 1 None
Pan-flavi unknown TibMolBiol (commercial) 1 None
Information not providedc 1 1 (lineage 1)
WNV: West Nile virus.
a WNV lineage missed indicated between brackets.
b Included in statistical analysis as classified as virus-specific real-time RT-PCR.
c Excluded from statistical analysis since cannot be classified as real-time RT-PCR or conventional RT-PCR.
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public health, have sympatric circulation (at least two 
of them) in several European countries and are indis-
tinguishable clinically. It is important to underline that 
most of the participating laboratories were not first-line 
routine laboratories but national reference laboratories 
[3]. The fact that samples were missed by laboratories 
is of concern as the samples had RNA loads within the 
average of clinical relevance and were not intended to 
be at the detection limit to evaluate sensitivity. Another 
worrisome observation is the fact that six of 51 par-
ticipating laboratories scored one or more of the viral 
RNA-negative samples positive, which is indicative of 
contamination issues and happened more frequently 
than in previous EQAs [21-23].
In our study, the total number of panels tested by 
each RT-PCR test did not allow statistically significant 
conclusions about specific methods that laboratories 
should be advised to use. Nevertheless, for TOSV and 
USUV, methods other than virus-specific real-time 
assays provided false-negative results more frequently 
than virus-specific real-time PCR tests. Although the 
same trend was not observed for WNV and TBEV, this 
could be taken into consideration by laboratories to 
improve the performance of their diagnostic capacity.
Because TOSV is endemic in countries surrounding the 
Mediterranean Sea, the majority of reference labora-
tories in Europe deal only with imported TOSV cases 
[24-28]. The neglected state of TOSV is reflected in the 
general absence of commercial tests, except for one 
which was used by one laboratory for the EQA panel. 
TOSV detection capacity had a geographical and lab-
oratory coverage comparable to USUV, i.e. 32 labora-
tories in 19 countries which included all participating 
countries with known TOSV circulation (Croatia, Cyprus, 
France, Greece, Italy, Portugal and Spain). Bosnia and 
Herzegovina and Kosovo*, two other European coun-
tries with TOSV activity, did not participate in the EQA. 
Three TOSV lineages circulate in Europe, two of which 
were represented in the EQA panel, i.e. lineages A 
Figure 3
Number of laboratories per country that provided results for Usutu virus, external quality assessment for molecular 
detection of emerging neurotropic viruses, Europe (n = 28 laboratories)
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and B. The third lineage, lineage C, has only recently 
been discovered in Greece and Croatia and could not 
be included in the panel because the virus isolate was 
not available at the time. Of the 32 laboratories that 
tested for TOSV, four laboratories in four countries 
missed the TOSV lineage B sample; another labora-
tory in a fifth country missed the lineage A sample. At 
RT-PCR test level, lineage A was missed with one test 
while lineage B was missed six times by five RT-PCR 
tests of which four were conventional RT-PCR meth-
ods, despite the fact that the samples had similar viral 
loads. Apparently some laboratories used systems that 
were not sensitive enough for detection of TOSV line-
age B strains, although this lineage is geographically 
most widely spread [4]. TOSV RNA loads provided in 
this EQA were in line with the virological findings in CSF 
[29-31,32,33]. The recent discovery of lineage C mer-
its attention and the capacity of currently described 
assays to detect such strains need to be verified; since 
virological and genetic characterisation of this lineage 
is ongoing in Greece, inclusion of this lineage will be 
possible in future EQAs. At the country level, three of 
the five laboratories that missed a TOSV RNA-positive 
sample were located in a country endemic for TOSV. 
Better insight into the capability of TOSV molecular 
detection in Europe should be obtained with a dedi-
cated EQA, including all three lineages at different viral 
loads, designed for a comparative evaluation of the 
RT-PCR methods described in the literature.
The widest geographical (32 countries) and laboratory 
(n = 48) coverage was for WNV testing. The WNV lineage 
1 sample was missed by five laboratories in five EU/
EEA countries that had never reported an autochtho-
nous WNV case, while WNV lineage 2 was missed by 
two laboratories in two EU/EEA countries, one of which 
is endemic for WNV lineage 2. This was the third EQA 
of molecular detection of WNV within EVD-LabNet and 
its predecessor ENIVD [22,23]. The long history of WNV 
capability assessments and surveillance in Europe is 
likely to explain the good scores observed with WNV.
In this panel, USUV was the most recent emerging 
virus with still accumulating evidence of its relevance 
for public health and an increasing geographical dis-
tribution [13]. This might explain why the testing capa-
bility for USUV had the smallest geographical coverage 
(n = 18 countries) and number of laboratories (n = 28 
laboratories). This was the first EQA that included 
USUV and there is no literature on clinically relevant 
viral loads in plasma. The concentration in this panel 
(1.6 × 104 copies/mL) was in the range of detected viral 
loads for the closely related WNV in plasma [34-36]. 
Looking at the currently known geographical distribu-
tion of USUV in Europe, all countries with USUV circula-
tion except Switzerland participated with USUV testing. 
The USUV-positive sample was missed by seven labo-
ratories in four EU/EEA countries. To gain better insight 
in the robustness of USUV detection in Europe, a dedi-
cated EQA including a concentration range of USUV 
genome copies in different matrices (whole blood, 
plasma and urine) is to be planned.
Although the geographical distribution of TBEV in 
Europe is broader than that of WNV and the total number 
of tick-borne encephalitis cases is higher, the number 
Table 5
RT-PCR methods used for Usutu virus RNA detection, external quality assessment for molecular detection of emerging 
neurotropic viruses, Europe (n = 28 laboratories)
Target Method Number of laboratories False-negative
Usutu virus-specific
USUV NS5 Nikolay et al., 2014 [58]a 11 1
USUV NS5 Cavrini et al., 2011 [59]a 5 none
USUV NS1 Jöst et al., 2011 [60]a 2 none
USUV NS5 Weissenböck et al., 2013 [61]a 1 none
USUV 3‘UTR Del Amo et al., 2013 [62]a 1 none
USUV unknown Own designb 4 none
Pan-flavivirus
Pan-flavi NS5 Scaramozzino et al., 2001 [51] 5 3
Pan-flavi NS5 Sanchez-Seco et al., 2005 [52] 3 3
Pan-flavi NS5 Patel et al., 2013 [54] 2 none
Pan-flavi NS5 Vina-Rodriguez et al., 2017 [56] 1 1
Pan-flavi NS5 Vazques et al., 2012 [57] 1 1
Pan-flavi unknown Own design 2 none
Pan-flavi unknown Genekam (commercial) 1 none
USUV: Usutu virus.
a Included in statistical analysis as classified as virus-specific real-time RT-PCR.
b Excluded from statistical analysis since cannot be classified as real-time RT-PCR or conventional RT-PCR.
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of laboratories participating with TBEV testing (n = 42) 
and their country coverage (n = 28) was smaller than for 
WNV. The TBEV sample was missed by four laborato-
ries in three countries, of which two display endemic 
presence of TBEV. This was the second EQA including 
molecular detection of TBEV within EVD-LabNet and its 
predecessor ENIVD [21]. However, overall results could 
not be compared as our EQA only assessed TBEV test-
ing based on one single RNA viral load.
Based on our results, we cannot give advice on what 
methods to use for the molecular detection of the four 
viruses. This requires assessment of the whole rou-
tine procedure from sample receipt to generation of a 
result. The performance in the EQA is a combination of 
the extraction method and the RT-PCR method used, 
as would routinely be the case when processing real-
life diagnostic samples. The set-up of the current EQA 
cannot assess the influence of the extraction method 
or RT-PCR system on the final outcome per sample. 
The background data provided by the participants 
indicated an important diversity of the methods used 
for nucleic acid extraction (19 methods). It was impos-
sible to link the extraction method to the quality of the 
results. To assess solely the quality of the RT-PCR, EQA 
panels consisting of extracted or synthetic RNA should 
be provided. Although our study was not designed to 
address the efficacy of the extraction technique per 
se, there are many arguments that favour automated 
extraction protocols over manual protocols. Automated 
extraction reduces the risk of cross-contamination, the 
turnaround and hands-on times, provide equivalent 
amounts of viral RNA and guarantee a better reproduc-
ibility compared with manual extraction [37–42]. EQA 
is an efficient tool to evaluate diagnostic procedures 
and to alert highlight where improvements are needed. 
Therefore, we recommend repeating the EQA for labora-
tories with unsatisfactory results, focusing at least on 
TOSV and USUV and investigating whether the required 
improvements are achieved. For these two viruses, we 
recommend real-time assays rather than classic or 
nested PCR protocols.
Figure 4
Number of laboratories per country that provided results for tick-borne encephalitis virus, external quality assessment for 
molecular detection of emerging neurotropic viruses, Europe (n = 42 laboratories)
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Conclusion
Early detection of neurotropic arboviruses allows for 
timely risk assessment and risk management measures. 
We observed wide variation in both extraction meth-
ods and RT-PCR tests, showing a profound absence of 
standardisation across European laboratories. Overall, 
the results were not satisfactory and indicated a need 
for improvement of capacity and capability. Testing for 
WNV and TBEV, for which EQAs had been organised 
previously, showed better results than testing for USUV 
and TOSV for which this EQA was the first. This trend 
is important to consider and suggests that EQA exer-
cises for TOSV and USUV should be repeated in order 
to assess whether successful improvements have been 
made.
*Note
This designation is without prejudice to positions on status, 
and is in line with UNSCR 1244 and the ICJ Opinion on the 
Kosovo Declaration of Independence
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